MCF Advisors LLC lessened its position in shares of Amgen Inc. (NASDAQ:AMGN) by 27.3% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,199 shares of the medical research company’s stock after selling 450 shares during the period. MCF Advisors LLC’s holdings in Amgen were worth $206,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the company. TrimTabs Asset Management LLC boosted its stake in shares of Amgen by 88.9% in the first quarter. TrimTabs Asset Management LLC now owns 612 shares of the medical research company’s stock valued at $100,000 after buying an additional 288 shares during the period. Alpha Omega Wealth Management LLC boosted its stake in shares of Amgen by 19.0% in the first quarter. Alpha Omega Wealth Management LLC now owns 625 shares of the medical research company’s stock valued at $103,000 after buying an additional 100 shares during the period. Jackson Grant Investment Advisers Inc. boosted its stake in shares of Amgen by 0.6% in the first quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock valued at $104,000 after buying an additional 4 shares during the period. American Beacon Advisors Inc. bought a new stake in shares of Amgen in the first quarter valued at approximately $106,000. Finally, Nelson Roberts Investment Advisors LLC bought a new stake in shares of Amgen in the first quarter valued at approximately $121,000. Institutional investors own 78.14% of the company’s stock.

Several equities research analysts recently issued reports on the company. BMO Capital Markets cut Amgen from an “outperform” rating to a “market perform” rating and set a $199.00 price target for the company. in a research note on Friday, July 21st. They noted that the move was a valuation call. Oppenheimer Holdings, Inc. restated a “buy” rating and set a $203.00 price objective on shares of Amgen in a research report on Thursday, September 7th. Jefferies Group LLC restated a “hold” rating and set a $180.00 price objective on shares of Amgen in a research report on Monday, May 22nd. Leerink Swann restated a “market perform” rating and set a $161.00 price objective on shares of Amgen in a research report on Thursday, June 22nd. Finally, Credit Suisse Group set a $177.00 price objective on shares of Amgen and gave the company a “hold” rating in a research report on Friday, July 14th. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating, twelve have issued a buy rating and two have given a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $186.04.

Amgen Inc. (NASDAQ AMGN) traded down 1.54% during trading on Wednesday, hitting $188.06. 1,585,077 shares of the stock were exchanged. The stock has a 50 day moving average of $174.23 and a 200-day moving average of $168.94. The stock has a market cap of $137.22 billion, a P/E ratio of 17.13 and a beta of 1.35. Amgen Inc. has a 52 week low of $133.64 and a 52 week high of $191.04.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share for the quarter, beating analysts’ consensus estimates of $3.11 by $0.16. The firm had revenue of $5.81 billion for the quarter, compared to analyst estimates of $5.67 billion. Amgen had a net margin of 35.46% and a return on equity of 29.85%. The company’s revenue for the quarter was up 2.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.84 EPS. Equities analysts expect that Amgen Inc. will post $12.57 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 8th. Investors of record on Thursday, August 17th were paid a dividend of $1.15 per share. This represents a $4.60 annualized dividend and a yield of 2.41%. The ex-dividend date was Tuesday, August 15th. Amgen’s payout ratio is currently 41.93%.

ILLEGAL ACTIVITY WARNING: “Amgen Inc. (AMGN) Shares Sold by MCF Advisors LLC” was first reported by Daily Political and is owned by of Daily Political. If you are reading this report on another publication, it was stolen and reposted in violation of US and international copyright & trademark laws. The original version of this report can be viewed at https://www.dailypolitical.com/2017/09/13/amgen-inc-amgn-shares-sold-by-mcf-advisors-llc.html.

About Amgen

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.